Loading…
Corvus Pharmaceuticals, Inc. is projected to rise to $17.68 by 2027, a +33% move from its current price of $13.26. CRVS is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $12.92 | $13.27 | $13.64 | +0.10% |
| Aug 3 | $12.78 | $13.29 | $13.81 | +0.20% |
| Aug 4 | $12.69 | $13.30 | $13.94 | +0.30% |
| Aug 5 | $12.61 | $13.31 | $14.06 | +0.40% |
| Aug 6 | $12.54 | $13.33 | $14.16 | +0.50% |
| Aug 7 | $12.48 | $13.34 | $14.26 | +0.59% |
| Aug 8 | $12.42 | $13.35 | $14.35 | +0.69% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $12.42 | $13.35 | $14.35 | +0.69% |
| Week 2 | $12.14 | $13.44 | $14.89 | +1.39% |
| Week 3 | $11.95 | $13.54 | $15.34 | +2.10% |
| Week 4 | $11.80 | $13.63 | $15.75 | +2.80% |
| Week 5 | $11.68 | $13.73 | $16.13 | +3.52% |
| Week 6 | $11.58 | $13.82 | $16.50 | +4.24% |
| Week 7 | $11.50 | $13.92 | $16.85 | +4.96% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that develops product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases.
The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of first line renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1 clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as license agreement with Scripps for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc.
was incorporated in 2014 and is based in South San Francisco, California.
Corvus Pharmaceuticals, Inc. (CRVS) is currently trading at $13.07 per share, with a market capitalization of $1.1B, and a market rank of 2325. This places the company among mid-cap healthcare players with a clinical stage development focus.
A major floor 28.4% below — a decisive break under it would weaken the trend.
The nearest floor, 10.2% below — buyers have tended to step in here.
The nearest ceiling, 22.2% above — a clean break opens room to run.
A major ceiling 36.3% above — clearing it would confirm fresh momentum.
Key CRVS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CRVS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $13.14 | Buy | $13.26 | Sell |
| MA 10 | $13.50 | Sell | $13.53 | Sell |
| MA 20 | $14.38 | Sell | $13.79 | Sell |
| MA 50 | $13.26 | Buy | $13.83 | Sell |
| MA 100 | $14.13 | Sell | $13.76 | Sell |
| MA 200 | $12.96 | Buy | $12.54 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.20 | Neutral |
| Stoch RSI (14) | 23.33 | Neutral |
| CCI (20) | -83.29 | Neutral |
| Williams %R (14) | -83.41 | Info |
| MACD (12,26,9) | -0.22 | Sell |
| ROC (12) | -11.13 | Sell |
| Bollinger %B (20,2) | 0.23 | Neutral |
| Stochastic %K (14) | 16.59 | Buy |
| TRIX (15) | 0.11 | Buy |
| Awesome (5,34) | -0.71 | Sell |
| Ultimate (7,14,28) | 35.78 | Neutral |
| Momentum (10) | -1.64 | Sell |
| Aroon Osc (25) | -48.00 | Sell |
| Hull MA (9) | 13.03 | Buy |
| ADX (14) | 17.76 | Neutral |
| ATR (14) | 0.36 | Info |
The technical picture is bullish, with sentiment tagged as BULLISH, and an RSI14 of 50. The stock trades around SMA50 of $13.31 and above SMA200 of $12.78, indicating constructive momentum on a near-term basis.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $6.50 | $13.26 | $18.72 | 0% | Neutral | |
| $14.10 | $17.68 | $23.44 | +33% | Bullish | |
| $16.49 | $21.27 | $29.28 | +60% | Bullish | |
| $18.07 | $23.85 | $33.80 | +80% | Bullish | |
| $17.91 | $24.14 | $35.06 | +82% | Bullish | |
| $20.15 | $27.67 | $41.05 | +109% | Bullish | |
| $22.44 | $31.34 | $47.40 | +136% | Bullish | |
| $26.89 | $38.19 | $58.76 | +188% | Bullish | |
| $32.19 | $46.43 | $72.59 | +250% | Bullish | |
| $31.70 | $46.39 | $73.62 | +250% | Bullish | |
| $50.09 | $78.40 | $132.34 | +491% | Bullish | |
| $82.78 | $145.41 | $268.60 | +997% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $6.50 | $13.26 | $16.49 | +0.00% |
| September 2026 | $11.74 | $13.89 | $16.90 | +4.76% |
| October 2026 | $12.18 | $14.51 | $17.84 | +4.45% |
| November 2026 | $12.60 | $15.09 | $18.71 | +3.99% |
| December 2026 | $12.44 | $14.98 | $18.72 | -0.73% |
Click any year to see its month-by-month CRVS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The CRVS price prediction for 2026 points to an average of $13.26 (low $6.50, high $18.72) — a potential gain of 0% on today's $13.26. A consolidation phase looks the most probable path here.
In 2027, CRVS is projected to trade between $14.10 and $23.44, averaging $17.68 — a potential gain of +33% from today's $13.26. That is up +33% on the projected 2026 average. Momentum favours further upside here.
Corvus Pharmaceuticals, Inc.'s 2028 outlook centres on $21.27, within a $16.49 to $29.28 range. That is up +20% on the projected 2027 average. That marks a +60% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, CRVS could reach as high as $33.80, with a base case around $23.85 and support toward $18.07 — roughly +80% from $13.26. Momentum favours further upside here.
Expect CRVS to range from $17.91 to $35.06 through 2030. The $24.14 average target implies a +82% move from current prices. That is up +1% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The CRVS price prediction for 2031 points to an average of $27.67 (low $20.15, high $41.05) — a potential gain of +109% on today's $13.26. Momentum favours further upside here.
In 2032, CRVS is projected to trade between $22.44 and $47.40, averaging $31.34 — a potential gain of +136% from today's $13.26. That is up +13% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Corvus Pharmaceuticals, Inc.'s 2033 outlook centres on $38.19, within a $26.89 to $58.76 range. That is up +22% on the projected 2032 average. That marks a +188% change versus current levels. Momentum favours further upside here.
By 2034, CRVS could reach as high as $72.59, with a base case around $46.43 and support toward $32.19 — roughly +250% from $13.26. Buyers look set to stay in control over this stretch.
Expect CRVS to range from $31.70 to $73.62 through 2035. The $46.39 average target implies a +250% move from current prices. That is 0% versus the projected 2034 average. Momentum favours further upside here.
The CRVS price prediction for 2040 points to an average of $78.40 (low $50.09, high $132.34) — a potential gain of +491% on today's $13.26. Buyers look set to stay in control over this stretch.
In 2050, CRVS is projected to trade between $82.78 and $268.60, averaging $145.41 — a potential gain of +997% from today's $13.26. That is up +85% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in CRVS today (≈ 75.414781 CRVS) could be worth
$10,965.87
+$9,965.87 (+997%) by 2050 · US Dollar
Based on the average projected CRVS price of $145.41 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CRVSwould be worth at today's price.
$1,000 invested in CRVS on Jul 31, 2025 (≈ 239.808149 CRVS) would be worth
$3,179.86
+$2,179.86 (+218.0%) today · 3.18× · US Dollar
Based on a CRVS entry price of $4.17 vs. today's $13.26.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $13.07 | $1,014.54 | +1.5% |
| 1 month ago | $14.76 | $898.37 | -10.2% |
| 3 months ago | $15.46 | $857.7 | -14.2% |
| 6 months ago | $20.98 | $632.03 | -36.8% |
| 1 year ago | $4.17 | $3,179.86 | +218.0% |
| All time (5.0y) ago | $2.14 | $6,196.26 | +519.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CRVS forecast.
Our base-case forecast reaches $27.00 around 2031.
Implied market cap at $27.00: $2.27B
The year-by-year forecast shows a rising pathway after 2026, with 2026 posting an average of 13.07 and a neutral sentiment. The path accelerates through 2027 (Avg 17.74; ROI 35.8), 2028 (Avg 21.26; ROI 62.6), 2029 (Avg 23.62; ROI 80.7), and 2030 (Avg 23.88; ROI 82.7). By 2031–2035, averages climb to 27.27, 30.97, 38.39, 46.57, and 45.97 respectively, with continued bullish sentiment.
The forecast continues to 2040 (Avg 79.17; ROI 505.8) and 2050 (Avg 143.25; ROI 996), with the long-range view remaining bullish. These figures are estimates, not guarantees, and reflect projected upside across multiple years.
Tap a question to reveal the answer.
Min $17.40, Avg $23.88, Max $35.40; ROI 82.7; sentiment BULLISH.
The forecast shows bullish sentiment from 2027 onward with rising averages and ROI, though 2026 is Neutral; these are estimates, not guarantees.
Yes, the forecast shows 2040 max $137.93 and 2050 max $274.66, with 2040 Avg $79.17 and 2050 Avg $143.25.
Current price is $13.07 per share; Market cap is $1.1B.
Min $6.50, Avg $13.07, Max $18.64; ROI 0; sentiment NEUTRAL.
Corvus Pharmaceuticals, Inc. Community Discussion
0Share your Corvus Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.